When do we choose semaglotide and when does terzipatide? EASO has just announced that it will update its algorithm with evidence until November 2025 Warning: It depends on the clinical goal. Tirzepatide, a dual GIP GLP 1 receptor co agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction Cardiovascular Diabetology Springer Nature Link Cagrilintide and semaglutide act individually on both EI and EE a, Download Scientific Diagram Unveiling the Therapeutic Potential of the Second Generation Incretin Analogs Semaglutide and Tirzepatide in Type 1 Diabetes and Latent Autoimmune Diabetes in Adults